Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: #ASCO18: Don’t write off IDO yet, says NewLink .Despite a run of poor results in clinical trials, IDO inhibition is still a worthy target to explore in cancer … Continue reading
Cet article #news #biotech #ASCO18: Don’t write off IDO yet, says NewLink est apparu en premier sur Biotech 365.
Original Article: #news #biotech #ASCO18: Don’t write off IDO yet, says NewLink